Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cu(II)ATSM Extension Study in ALS
NCT03136809Phase 2Unknown
- Sponsor
- Vivat Therapeutics
- Start
- Jan 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CuATSM in amyotrophic lateral sclerosis (ALS), sponsored by Vivat Therapeutics. Status: unknown.
02
Drugs
CuATSM
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03136809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03136809.